This list is an analysis based on recent market events. It's not an investment recommendation.
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
FAQs
What is Corline Biomedical AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Corline Biomedical AB stocks are traded under the ticker CLBIO-BTA.ST.
When is the next Corline Biomedical AB earnings date?▼
Corline Biomedical AB is going to release the next earnings report on November 19, 2026.
What is Corline Biomedical AB revenue for the last year?▼
Corline Biomedical AB revenue for the last year amounts to 7.65M SEK.
What is Corline Biomedical AB net income for the last year?▼
CLBIO-BTA.ST net income for the last year is -14.71M SEK.
How many employees does Corline Biomedical AB have?▼
As of November 3, 2026, the company has 14 employees.
In which sector is Corline Biomedical AB located?▼
Corline Biomedical AB operates in the Health & Wellness sector.
When did Corline Biomedical AB complete a stock split?▼
Corline Biomedical AB has not had any recent stock splits.
Where is Corline Biomedical AB headquartered?▼
Corline Biomedical AB is headquartered in Uppsala, Sweden.